<DOC>
	<DOCNO>NCT00291577</DOCNO>
	<brief_summary>This study evaluate safety SU011248 ( Sunitinib/Sutent ) combination docetaxel patient metastatic locally recurrent breast cancer receive chemotherapy treatment advance disease setting .</brief_summary>
	<brief_title>Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Breast cancer evidence unresectable , locally recurrent metastatic disease Candidate treatment docetaxel Prior chemotherapy advance disease set Inflammatory breast cancer HER2 positive disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>advanced</keyword>
	<keyword>sunitinib ( Sutent )</keyword>
	<keyword>docetaxel</keyword>
	<keyword>Phase 1B</keyword>
</DOC>